NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Price Target & More

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) posted its earnings results on Friday, March, 2nd. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04. Eyegate Pharmaceuticals had a negative return on equity of 653.57% and a negative net margin of 2,480.28%. View Eyegate Pharmaceuticals' Earnings History.

1 brokerages have issued 1-year target prices for Eyegate Pharmaceuticals' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Eyegate Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Ratings for Eyegate Pharmaceuticals.

Eyegate Pharmaceuticals saw a decline in short interest in the month of April. As of April 30th, there was short interest totalling 980,874 shares, a decline of 40.5% from the April 13th total of 1,647,564 shares. Based on an average daily volume of 2,785,591 shares, the short-interest ratio is presently 0.4 days. Approximately 3.6% of the shares of the stock are sold short.

Some companies that are related to Eyegate Pharmaceuticals include Ophthotech (OPHT), CytoDyn (CYDY), VIVUS (VVUS), Sesen Bio (SESN), Columbia Laboratories (JNP), KalVista Pharmaceuticals (KALV), KemPharm (KMPH), BioLineRx (BLRX), Advaxis (ADXS), Cumberland Pharmaceuticals (CPIX), Northwest Biotherapeutics (NWBO), Galmed Pharmaceuticals (GLMD), Gemphire Therapeutics (GEMP), Sunesis Pharmaceuticals (SNSS) and Axsome Therapeutics (AXSM).

(EYEG) raised $5 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.

Press coverage about EYEG stock has trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eyegate Pharmaceuticals earned a daily sentiment score of 0.16 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 45.66 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Eyegate Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include ARMISTICE CAPITAL, LLC (40.20%), ARMISTICE CAPITAL, LLC (50.80%) and ARMISTICE CAPITAL, LLC (4.99%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Morton Goldberg, Sarah Romano, Stephen From and Ventech Capital Ii. View Institutional Ownership Trends for Eyegate Pharmaceuticals.

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EYEG stock can currently be purchased for approximately $0.59.

Eyegate Pharmaceuticals has a market capitalization of $25.70 million and generates $410,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,210,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Eyegate Pharmaceuticals employs 17 workers across the globe.

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.